Neurocrine biosciences presents ingrezza® (valbenazine) capsules data on tardive dyskinesia improvement regardless of baseline antipsychotic use at 2023 psych congress elevate

San diego , june 2, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today presented findings from a meta-analysis of three long-term studies evaluating ingrezza® (valbenazine) capsules that demonstrated substantial and sustained improvements in tardive dyskinesia (td) in adults with or without concomitant antipsychotic therapy. the data (poster #4) were presented at 2023 psych congress elevate in las vegas.
NBIX Ratings Summary
NBIX Quant Ranking